Newsbenzinga
Keros Therapeutics Q3 GAAP EPS $0.70 vs $(0.18) YoY, Includes $40.0M Takeda License Revenue; Revenue $40.01M vs $14.26M YoY
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…